US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
EP0381759A4
(en)
|
1988-07-25 |
1990-12-12 |
Vsesojuzny Kurgansky Nauchny Tsentr "Vosstanovitelnaya Travmatologia I Ortopedia" |
Traction apparatus for restoring the shape of the hand
|
TW219933B
(es)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
DE59401923D1
(de)
|
1993-11-02 |
1997-04-10 |
Hoechst Ag |
Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
ES2101421T3
(es)
|
1993-11-02 |
1997-07-01 |
Hoechst Ag |
Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
|
NZ270267A
(en)
|
1993-12-30 |
1997-03-24 |
Hoechst Ag |
3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
JP2000509047A
(ja)
|
1996-04-30 |
2000-07-18 |
ヘキスト・アクチエンゲゼルシヤフト |
3―アルコキシピリジン―2―カルボキサミドエステル類、その製法および薬剤としてのその使用
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
CN1282319A
(zh)
|
1997-10-09 |
2001-01-31 |
小野药品工业株式会社 |
氨基丁酸衍生物
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
WO1999048870A1
(en)
|
1998-03-23 |
1999-09-30 |
Aventis Pharmaceuticals Products Inc. |
Piperididinyl and n-amidinopiperidinyl derivatives
|
SI20581B
(sl)
|
1998-08-27 |
2008-06-30 |
Teva Pharma |
Nove hidratne oblike natrijevega alendronata, postopki za njihovo pridobivanje in ustrezne farmacevtske učinkovine
|
US6500987B1
(en)
|
1998-11-27 |
2002-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride polymorphs
|
JP2002531427A
(ja)
|
1998-11-27 |
2002-09-24 |
テバ ファーマシューティカル インダストリーズ リミティド |
セルトラリン塩酸塩多形体
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
WO2001010441A1
(en)
|
1999-08-11 |
2001-02-15 |
Teva Pharmaceutical Industries Ltd. |
Torsemide polymorphs
|
SI1235799T1
(en)
|
1999-11-17 |
2005-06-30 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
CZ20021998A3
(cs)
|
1999-12-14 |
2003-02-12 |
Biogal Gyogyszergyar Rt. |
Nové formy sodné soli pravastatinu
|
PL356243A1
(en)
|
1999-12-16 |
2004-06-28 |
Teva Pharmaceuticals Industries Ltd. |
Novel processes for making- and a new crystalline form of- leflunomide
|
RU2002116232A
(ru)
|
1999-12-16 |
2004-01-10 |
Тева Фамэситикл Индастрис Лтд. (Il) |
Способ получения полиморфных модификаций кларитромицина и новой полиморфной модификации IV
|
KR100791872B1
(ko)
|
1999-12-21 |
2008-01-07 |
테바 파마슈티컬 인더스트리즈 리미티드 |
신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법
|
MXPA02006660A
(es)
*
|
2000-01-07 |
2002-12-13 |
Transform Pharmaceuticals Inc |
Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
|
EP1280535B1
(en)
|
2000-01-11 |
2005-02-09 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing clarithromycin polymorphs
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
DK1309547T3
(da)
|
2000-07-27 |
2007-05-21 |
Teva Pharma |
Krystallinsk og ren modafinil og fremgangsmåde til fremstilling af samme
|
CZ20031298A3
(cs)
|
2000-10-19 |
2003-10-15 |
Teva Pharmaceutical Industries Ltd. |
Způsob přípravy krystalické báze venlafaxinu a nových polymorfů hydrochloridu venlafaxinu
|
US20020183553A1
(en)
|
2000-10-19 |
2002-12-05 |
Ben-Zion Dolitzky |
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
|
CN1498216A
(zh)
|
2000-10-30 |
2004-05-19 |
������ҩ��ҵ����˾ |
新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法
|
IL155734A0
(en)
|
2000-11-03 |
2003-11-23 |
Teve Pharmaceutical Ind Ltd |
Atorvastatin hemi-calcium form vii
|
IL156055A0
(en)
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
US7501450B2
(en)
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
WO2002064557A2
(en)
|
2001-02-12 |
2002-08-22 |
Teva Pharmaceutical Industries Ltd. |
New crystal forms of oxcarbazepine and processes for their preparation
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
AU2002241154A1
(en)
|
2001-03-21 |
2002-10-03 |
Isis Innovation Ltd. |
Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
|
AU2002305162A1
(en)
|
2001-04-09 |
2002-10-21 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of fexofenadine hydrochloride
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
SK472004A3
(en)
|
2001-08-01 |
2004-12-01 |
Biogal Gyogyszergyar |
Purification and crystalline forms of zaleplon
|
CN1551880A
(zh)
|
2001-09-07 |
2004-12-01 |
������ҩ��ҵ����˾ |
阿昔洛韦缬氨酸酯盐酸盐的晶型
|
JP2005504818A
(ja)
|
2001-10-03 |
2005-02-17 |
テバ ファーマシューティカル インダストリーズ リミティド |
レボフロキサシンおよびその形態の調製
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
EP1453509A2
(en)
|
2001-11-08 |
2004-09-08 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of fexofenadine base
|
CA2672549A1
(en)
|
2001-11-14 |
2003-06-12 |
Ben-Zion Dolitzky |
Amorphous and crystalline forms of losartan potassium and process for their preparation
|
AU2002362061A1
(en)
|
2001-12-04 |
2003-06-17 |
Biogal Gyogyszergyar Rt |
Preparation of orlistat and orlistat crystalline forms
|
EP1463823B1
(en)
|
2001-12-06 |
2013-03-06 |
Fibrogen, Inc. |
Methods of increasing endogenous erythropoietin (epo)
|
EP1467735B1
(en)
|
2001-12-18 |
2008-12-10 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of clopidogrel hydrogensulfate
|
IL162457A0
(en)
|
2001-12-28 |
2005-11-20 |
Biogal Pharmaceutical Co |
Processes for preparing crystalline and amorphous mupirocin calcium
|
WO2003059807A2
(en)
|
2002-01-15 |
2003-07-24 |
Teva Pharmaceutical Industries Ltd. |
Crystalline solids of carvedilol and processes for their preparation
|
DE03713610T1
(de)
|
2002-02-15 |
2005-10-20 |
Teva Pharma |
Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
|
WO2003080065A1
(en)
|
2002-03-20 |
2003-10-02 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of quetiapine hemifumarate
|
WO2003082857A2
(en)
|
2002-03-27 |
2003-10-09 |
Teva Pharmaceutical Industries Ltd. |
Lansoprazole polymorphs and processes for preparation thereof
|
WO2003086355A1
(en)
|
2002-04-11 |
2003-10-23 |
Teva Pharmaceutical Indudstries, Ltd. |
Novel polymorphs and pseudopolymorphs of risedronate sodium
|
AU2003251290A1
(en)
|
2002-04-29 |
2003-11-17 |
Teva Pharmaceutical Industries Ltd. |
Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
|
JP2005529908A
(ja)
|
2002-04-30 |
2005-10-06 |
テバ ジョジセルジャール レースベニュタールシャシャーグ |
オンダンセトロンの新規結晶形、その製法、当該新規形を含有する医薬組成物、及び当該組成物を用いる吐気の治療方法
|
EP1503762A2
(en)
|
2002-05-10 |
2005-02-09 |
Teva Pharmaceutical Industries Ltd. |
Novel crystalline forms of gatifloxacin
|
AU2003248657A1
(en)
|
2002-06-10 |
2003-12-22 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form xvi of fexofenadine hydrochloride
|
EP1471911A1
(en)
|
2002-06-14 |
2004-11-03 |
Teva Pharmaceutical Industries Ltd. |
Novel crystalline forms of gatifloxacin
|
US7534913B2
(en)
|
2002-07-18 |
2009-05-19 |
Teva Pharmaceutica Industries Ltd. |
Crystalline form of nateglinide
|
WO2004009532A1
(en)
|
2002-07-18 |
2004-01-29 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
US20040022764A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Hanan Polansky |
Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
|
EP1545530A1
(en)
|
2002-08-06 |
2005-06-29 |
Teva Pharmaceutical Industries Limited |
Novel crystalline forms of gatifloxacin
|
AU2003268213A1
(en)
|
2002-08-26 |
2004-03-11 |
Teva Pharmaceutical Industries Ltd. |
Crystalline solid famciclovir forms i, ii, iii and preparation thereof
|
US20050043329A1
(en)
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
AU2003297594A1
(en)
|
2002-11-28 |
2004-06-23 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form f of atorvastatin hemi-calcium salt
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
JP2006511618A
(ja)
|
2002-12-12 |
2006-04-06 |
テバ ファーマシューティカル インダストリーズ リミティド |
ガチフロキサシンの結晶形態および調製の方法
|
AU2003300324A1
(en)
|
2002-12-24 |
2004-07-22 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
|
ES2245277T1
(es)
|
2003-03-12 |
2006-01-01 |
Teva Pharmaceutical Industries Limited |
Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
|
US20040242619A1
(en)
|
2003-03-12 |
2004-12-02 |
Toth Zoltan G. |
Processes for preparation of polymorphic forms of desloratadine
|
ES2238022T3
(es)
|
2003-03-17 |
2008-11-01 |
Teva Pharmaceutical Industries Ltd. |
Poliformos de valsartan.
|
WO2004103999A1
(en)
|
2003-05-15 |
2004-12-02 |
TEVA Gyógyszergyár Részvénytársaság |
AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
|
WO2005000850A2
(en)
|
2003-06-02 |
2005-01-06 |
Teva Pharmaceutical Industries, Ltd. |
Novel crystalline forms of valacyclovir hydrochloride
|
CA2528192A1
(en)
|
2003-06-03 |
2005-02-24 |
Teva Pharmaceutical Industries Ltd |
Cristalline ziprasidone hcl and processes for preparation thereof
|
BRPI0411055B1
(pt)
|
2003-06-06 |
2018-08-21 |
Fibrogen, Inc |
Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
|
US7368468B2
(en)
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
CA2613021A1
(en)
|
2003-06-18 |
2004-12-29 |
Teva Pharmaceutical Industries Ltd |
Fluvastatin sodium crystal form lxxx, processes for preparing, compositions and methods of using
|
DE602004019881D1
(de)
|
2003-07-03 |
2009-04-23 |
Teva Pharma |
Kristallformen der zoledronsäure und deren natrioumsalze, amorphes natriumzoledronat und verfahren zu deren herstellung
|
US7777034B2
(en)
|
2003-11-24 |
2010-08-17 |
Teva Pharmaceutical Industries Ltd. |
Crystalline ammonium salts of rosuvastatin
|
US7504504B2
(en)
|
2003-12-16 |
2009-03-17 |
Teva Pharmaceutical Industries Ltd. |
Methods of preparing aripiprazole crystalline forms
|
US20050165085A1
(en)
|
2003-12-16 |
2005-07-28 |
Marioara Mendelovici |
Polymorphic forms of tegaserod base and salts thereof
|
US20050197347A1
(en)
|
2003-12-18 |
2005-09-08 |
Judith Aronhime |
Polymorphic form B2 of ziprasidone base
|
EP1709002A2
(en)
|
2004-01-30 |
2006-10-11 |
Teva Pharmaceutical Industries Ltd. |
Montelukast sodium polymorphs
|
WO2005074935A1
(en)
|
2004-01-30 |
2005-08-18 |
Teva Pharmaceutical Industries Ltd. |
Montelukast free acid polymorphs
|
WO2005077941A2
(en)
|
2004-02-11 |
2005-08-25 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
WO2005108370A1
(ja)
|
2004-04-16 |
2005-11-17 |
Ajinomoto Co., Inc. |
ベンゼン化合物
|
EP1628959A2
(en)
|
2004-04-26 |
2006-03-01 |
Teva Pharmaceutical Industries Ltd |
Crystalline forms of fexofenadine hydrochloride and processes for their preparation
|
US20060004102A1
(en)
|
2004-05-07 |
2006-01-05 |
Shlomit Wizel |
Polymorphic forms of nateglinide
|
KR20080091298A
(ko)
|
2004-05-18 |
2008-10-09 |
테바 파마슈티컬 인더스트리즈 리미티드 |
결정성 고체 팜시클로버의 제조를 위한 건조방법
|
US20050272821A1
(en)
|
2004-05-20 |
2005-12-08 |
Valeriano Merli |
Levalbuterol hydrochloride Polymorph A
|
MX2007000087A
(es)
|
2004-06-23 |
2007-11-06 |
Teva Pharma |
Acido ibandronico solido y cristalino.
|
US20060142283A1
(en)
|
2004-06-29 |
2006-06-29 |
Judith Aronhime |
Crystalline form IV of linezolid
|
KR20070034080A
(ko)
|
2004-07-01 |
2007-03-27 |
테바 파마슈티컬 인더스트리즈 리미티드 |
1,24(s)-디히드록시 비타민 d2의 결정형
|
CA2573781A1
(en)
|
2004-07-20 |
2006-02-02 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Processes for preparation of crystalline mycophenolate sodium
|
JP2007505944A
(ja)
|
2004-07-22 |
2007-03-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
アトルバスタチンヘミカルシウム及びその調製の方法
|
CN1976894A
(zh)
|
2004-07-22 |
2007-06-06 |
特瓦药物精化学品股份有限公司 |
阿托莫西汀盐酸盐的多形体
|
PT1713489E
(pt)
|
2004-08-23 |
2011-03-03 |
Teva Pharma |
Forma cristalina de ibandronato de sódio e processos para a sua preparação
|
JP2007513889A
(ja)
|
2004-09-21 |
2007-05-31 |
テバ ファーマシューティカル インダストリーズ リミティド |
結晶性クロピドグレル臭酸塩及びその調製方法
|
JP2008514641A
(ja)
|
2004-09-28 |
2008-05-08 |
テバ ファーマシューティカル インダストリーズ リミティド |
結晶形フェキソフェナジン、およびその調製方法
|
CA2582092A1
(en)
|
2004-11-02 |
2006-05-11 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil crystal forms and processes for preparing them
|
JP2008516001A
(ja)
|
2004-11-03 |
2008-05-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
非晶質、および多形のフォームのテルミサルタン・ナトリウム
|
US20060211751A1
(en)
|
2004-11-19 |
2006-09-21 |
Reuven Izsak |
Zolmitriptan crystal forms
|
US7439252B2
(en)
|
2004-12-01 |
2008-10-21 |
TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság |
Ascomycin crystalline forms and preparation thereof
|
JP2007526251A
(ja)
|
2004-12-03 |
2007-09-13 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミベ多形体
|
PT1836157E
(pt)
|
2005-01-11 |
2009-11-24 |
Teva Pharm Fine Chemicals Srl |
Polimorfos de cloridrato de memantina
|
EP1776049A2
(en)
|
2005-01-27 |
2007-04-25 |
Teva Pharmaceutical Industries Ltd. |
Duloxetine hcl polymorphs
|
WO2006084210A2
(en)
|
2005-02-04 |
2006-08-10 |
Regents Of The University Of California, San Diego |
Hif modulating compounds and methods of use thereof
|
US7335685B2
(en)
|
2005-02-24 |
2008-02-26 |
Teva Pharmaceutical Industries, Ltd. |
Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
|
US7291614B2
(en)
|
2005-02-24 |
2007-11-06 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of linezolid intermediate
|
EP1856087A1
(en)
|
2005-03-08 |
2007-11-21 |
Teva Pharmaceutical Industries Limited |
Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
|
US20060270684A1
(en)
|
2005-03-14 |
2006-11-30 |
Judith Aronhime |
Crystalline forms of ziprasidone mesylate
|
WO2006108151A1
(en)
|
2005-04-06 |
2006-10-12 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of pregabalin
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
MX349340B
(es)
|
2005-05-23 |
2017-07-24 |
Intercontinental Great Brands Llc |
Composiciones potenciadoras del sabor y bebidas que contienen las mismas.
|
MX2007000983A
(es)
|
2005-05-23 |
2007-04-16 |
Teva Pharma |
Procesos para preparar la forma cristalina i de clorhidrato de cinacalcet.
|
CA2610956A1
(en)
|
2005-06-06 |
2006-12-14 |
Fibrogen, Inc. |
Improved treatment for anemia using a hif-alpha stabilising agent
|
EP1781611A1
(en)
|
2005-06-09 |
2007-05-09 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of carvedilol and processes for their preparation
|
WO2007008317A2
(en)
|
2005-06-09 |
2007-01-18 |
Teva Pharmaceutical Industries Ltd. |
Process for preparation of sertraline hydrochloride form i
|
ATE470439T1
(de)
|
2005-06-15 |
2010-06-15 |
Fibrogen Inc |
Verwendung von hif 1alfa modulatoren zur behandlung von krebs
|
JP2008514734A
(ja)
|
2005-06-22 |
2008-05-08 |
テバ ファーマシューティカル インダストリーズ リミティド |
マレイン酸テガセロドの多型体
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
WO2007038676A2
(en)
|
2005-09-28 |
2007-04-05 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of ladostigil tartrate
|
WO2007047194A2
(en)
|
2005-10-11 |
2007-04-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating mitf-related disorders
|
SI1937642T1
(sl)
|
2005-10-19 |
2015-01-30 |
Teva Pharmaceutical Industries Ltd. |
Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
|
KR20070088764A
(ko)
|
2005-10-31 |
2007-08-29 |
테바 파마슈티컬 인더스트리즈 리미티드 |
세프디니어 칼륨염의 결정형
|
EP1828208A2
(en)
|
2005-10-31 |
2007-09-05 |
Teva Pharmaceutical Industries Ltd |
Crystalline form of cefdinir cesium salt
|
WO2007059307A2
(en)
|
2005-11-15 |
2007-05-24 |
Teva Pharmaceutical Industries Ltd. |
Crystalline and amorphous forms of telithromycin
|
KR20080055990A
(ko)
|
2005-11-22 |
2008-06-19 |
테바 파마슈티컬 인더스트리즈 리미티드 |
시나칼셋 HCl의 결정형 및 이의 제조 방법
|
AU2006326662B2
(en)
|
2005-12-09 |
2011-07-28 |
Amgen Inc. |
Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
|
US8080672B2
(en)
|
2005-12-13 |
2011-12-20 |
Teva Pharmaceutical Industries Ltd. |
Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
|
EP1861397A2
(en)
|
2006-01-05 |
2007-12-05 |
TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Production of dolasetron
|
BRPI0706377A2
(pt)
|
2006-01-09 |
2011-03-22 |
Btg Int Ltd |
moduladores de fator -1 induzìvel por hipoxia e usos relacionados
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
US20070225507A1
(en)
|
2006-01-18 |
2007-09-27 |
Gustavo Frenkel |
Process for preparing a crystalline form of Tegaserod maleate
|
US20070208053A1
(en)
|
2006-01-19 |
2007-09-06 |
Arnold Lee D |
Fused heterobicyclic kinase inhibitors
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
JP2009508880A
(ja)
|
2006-02-21 |
2009-03-05 |
テバ ファーマシューティカル インダストリーズ リミティド |
アルモダフィニルの新規な結晶形とその調製方法
|
ES2300236T1
(es)
|
2006-02-27 |
2008-06-16 |
Teva Pharmaceutical Industries Ltd |
Formas novedosas de fluvastatina sodica y su preparacion.
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
TW200808793A
(en)
|
2006-03-07 |
2008-02-16 |
Smithkline Beecham Corp |
Prolyl hydroxylase inhibitors
|
WO2007109799A2
(en)
|
2006-03-23 |
2007-09-27 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
WO2007136990A2
(en)
|
2006-05-16 |
2007-11-29 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
TWI394747B
(zh)
|
2006-06-23 |
2013-05-01 |
Smithkline Beecham Corp |
脯胺醯基羥化酶抑制劑
|
PL3357911T3
(pl)
*
|
2006-06-26 |
2022-09-05 |
Akebia Therapeutics Inc. |
Inhibitory prolilohydroksylazy i sposoby ich użycia
|
TW200845994A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: prolyl hydroxylase inhibitors
|
TW200845991A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: hydroxylase inhibitors
|
AU2008241503A1
(en)
|
2007-04-18 |
2008-10-30 |
Merck Sharp & Dohme Corp. |
Novel 1,8-naphthyridine compounds
|
AU2008241577B2
(en)
|
2007-04-18 |
2011-04-07 |
Amgen Inc. |
Indanone derivatives that inhibit prolyl hydroxylase
|
AU2008248234B2
(en)
|
2007-05-04 |
2011-02-03 |
Amgen Inc. |
Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
|
US8309544B2
(en)
|
2007-05-16 |
2012-11-13 |
Merck Sharp & Dohme Corp. |
Spiroindalones
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
CN101815718A
(zh)
|
2007-08-10 |
2010-08-25 |
克里斯捷诺米有限公司 |
吡啶衍生物及其用法
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
CN101918444A
(zh)
|
2007-11-08 |
2010-12-15 |
健泰科生物技术公司 |
抗因子b抗体及其用途
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
CN101983384A
(zh)
|
2007-11-30 |
2011-03-02 |
葛兰素史密斯克莱有限责任公司 |
脯氨酰羟化酶抑制剂
|
EP2224926A4
(en)
|
2007-11-30 |
2010-12-01 |
Glaxosmithkline Llc |
INHIBITORS OF PROLYL HYDROXYLASES
|
WO2009073669A1
(en)
|
2007-12-03 |
2009-06-11 |
Fibrogen, Inc. |
Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
|
WO2009086044A1
(en)
|
2007-12-19 |
2009-07-09 |
Smith Kline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
US20110003013A1
(en)
|
2008-01-04 |
2011-01-06 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
EP2252619B1
(en)
|
2008-01-11 |
2013-10-09 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
|
AR071997A1
(es)
*
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
MX2013014310A
(es)
|
2011-06-06 |
2014-01-23 |
Akebia Therapeutics Inc |
Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
|
NO2686520T3
(es)
|
2011-06-06 |
2018-03-17 |
|
|
AU2012289429B2
(en)
|
2011-07-22 |
2016-07-28 |
Beijing Betta Pharmaceuticals Co., Ltd |
Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
|
US8772895B2
(en)
|
2011-11-28 |
2014-07-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Dark current reduction for back side illuminated image sensor
|
EP2637274B1
(en)
|
2012-03-05 |
2022-05-04 |
Vetco Gray Scandinavia AS |
Power cable termination arrangement
|
CA2914662C
(en)
|
2013-06-13 |
2022-05-31 |
Robert Shalwitz |
Compositions and methods for treating anemia
|
BR112016011065B1
(pt)
|
2013-11-15 |
2022-10-25 |
Akebia Therapeutics, Inc |
Composto cristalino e seu uso, composição farmacêutica e seu uso, forma de dosagem, método para preparar um composto
|
EP3096617A4
(en)
|
2014-01-23 |
2017-09-13 |
Akebia Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
WO2016118858A1
(en)
|
2015-01-23 |
2016-07-28 |
Akebia Therapeutics, Inc. |
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
|
CA2979985A1
(en)
|
2015-03-20 |
2016-09-29 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
PE20180189A1
(es)
|
2015-04-01 |
2018-01-23 |
Akebia Therapeutics Inc |
Composiciones y metodos para el tratamiento de la anemia
|
ES2831863T3
(es)
|
2016-12-13 |
2021-06-09 |
Crystal Pharmaceutical Suzhou Co Ltd |
Nuevas formas cristalinas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético y procesos de preparación de las mismas
|
MX2020011845A
(es)
|
2018-05-09 |
2021-01-15 |
Akebia Therapeutics Inc |
Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
|
WO2021087144A1
(en)
|
2019-10-31 |
2021-05-06 |
Akebia Therapeutics, Inc. |
Therapeutic methods using vadadustat
|
US11524939B2
(en)
|
2019-11-13 |
2022-12-13 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
|